Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2008

01-02-2008 | Short Communication

Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?

Authors: R. B. Baleeiro, P. C. Bergami-Santos, M. Y. Tomiyoshi, J. L. Gross, F. Haddad, C. A. L. Pinto, F. A. Soares, R. N. Younes, J. A. M. Barbuto

Published in: Cancer Immunology, Immunotherapy | Issue 2/2008

Login to get access

Abstract

The present paper shows, for the first time, the membrane expression of the dendritic cell maturation marker CD83 on tumor cells from lung cancer patients. CD83 was also detected on freshly cultured fibroblast-like cells from these tissues and on several adherent human tumor cell lines (lung adenocarcinomas P9, A459 and A549, melanomas A375 and C81-61, breast adenocarcinomas SKBR-3 and MCF-7 and colon carcinoma AR42-J), but not in the non-adherent MOT leukemia cell line. CD83 may have immunosuppressive properties and its expression by cancer cells could have a role in facilitating tumor growth.
Literature
1.
Engelmayer J, Larson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N (1999) Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism immune evasion. J Immunol 163:6762PubMed
2.
Fugier-Vivier I, Servet-Delprat C, Rivailler P, Riossan MC, Liu YJ, Rabourdin-Combe C (1997) Measle virus suppresses cell mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 186:813PubMedCrossRef
3.
Hirano N, Butler MO, Xia Z, Anse´n S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM (2006) Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107:1528PubMedCrossRef
4.
Hock BD, Haring LF, Steinkasserer A, Taylor KG, William N, Patton WN, McKenzie JL (2004) The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res 28:237PubMedCrossRef
5.
Hock BD, Kato M, McKenzie JL, Hart DN (2001) A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol 13:959PubMedCrossRef
6.
Jenne L, Schuler G, Steinkasserer A (2001) Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22:102PubMedCrossRef
7.
Knight SC, Paderson S (1997) Bone marrow-derived dendritic cells infection with human immunodeficiency virus and immunopathology. Annu Rev Immunol 15:593PubMedCrossRef
8.
Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G, Hauber J, Steinkasserer A (2000) Mature dendritic cells infected with Herpes Simplex virus type 1 exhibit inhibited T cell stimulatory capacity. J Virol 74:7127PubMedCrossRef
9.
Lechmann M, Krooshoop DJ, Dudziak D, Kremmer E, Kuhnt C, Figdor CG et al (2001) The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 194:1813PubMedCrossRef
10.
Sorg UR, Morse TM, Patton WN, Hock BD, Angus HB, Robinson BA (1997) Hodgkin’s cells express CD83, a dendritic cell lineage associated antigen. Pathology 29:294PubMedCrossRef
11.
Scholler N, Hayden-Ledbetter M, Hellstrom KE, Hellstrom I, Ledbetter JA (2001) CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J Immunol 166:3865PubMed
12.
Scholler N, Hayden-Ledbetter M, Dahlin A, Hellstrom I, Hellstrom KE, Ledbetter JA (2002) Cutting edge: CD83 regulates the development of cellular immunity. J Immunol 168:2599PubMed
13.
Sénéchal B, Boruchov AM, Reagan JL, Hart DNJ, Young JW (2004) Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 103:4207PubMedCrossRef
14.
Yamashiro S, Wang JM, Yang D, Gong WH, Kamohara H, Yoshimura T (2000) Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 96:3958PubMed
15.
Zhou L, Schwarting R, Smith HM, Tedder TF (1992) A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol 149:735PubMed
16.
Zhou LJ, Tedder TF (1995) Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154:3821PubMed
17.
Zinser E, Lechmann M, Golka A, Lutz MB, Steinkasserer A (2004) Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med 200:345PubMedCrossRef
Metadata
Title
Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?
Authors
R. B. Baleeiro
P. C. Bergami-Santos
M. Y. Tomiyoshi
J. L. Gross
F. Haddad
C. A. L. Pinto
F. A. Soares
R. N. Younes
J. A. M. Barbuto
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0344-x

Other articles of this Issue 2/2008

Cancer Immunology, Immunotherapy 2/2008 Go to the issue

Original Article

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein

Original Article

Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells

Original Article

CRMP5 antibodies in patients with small-cell lung cancer or thymoma

Original Article

Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci

Original Article

New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen

Original Article

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits